Literature DB >> 11779836

Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Emily N Manderson1, Anne-Marie Mes-Masson, Jaroslav Novak, Peter D Lee, Diane Provencher, Thomas J Hudson, Patricia N Tonin.   

Abstract

We have investigated previously the utility of oligonucleotide expression microarray technology in an analysis of four spontaneously transformed epithelial ovarian cancer (EOC) cell lines, TOV-21G, TOV-81D, OV-90, and TOV-112D. Here, we examine the expression of 290 expressed sequence tags (ESTs) that map to human chromosome 3 in a primary culture derived from normal ovarian surface epithelium (NOSE), NOV-31, and the four spontaneously transformed EOC cell lines. One of these cell lines, OV-90, harbors a deletion of an entire chromosome 3p arm. Whereas the most aggressive cell lines (OV-90, TOV-112D, and TOV-21G) exhibited the highest levels of expression, assessed by the mean of expression values of all ESTs, OV-90 showed the lowest mean of expression of ESTs that map to the 3p arm in comparison with TOV-112D and TOV-21G. This difference in expression profile of 3p ESTs in OV-90 is also reflected in the ratio of expression of ESTs on 3p versus the 3q arm and in that the expression values of ESTs that map to 3p were more often lower than higher in OV-90 in two-way comparisons with NOV-31, TOV-21G, and TOV-112D. The loss of a 3p arm does not affect the pattern of differential expression in analyses based on the range of numeric expression values of each EST or fold differences in expression for each EST in comparison with NOV-31. However, 25 differentially expressed ESTs were identified on the basis of threefold differences in expression values between NOV-31 and any EOC cell line; and six of these ESTs were differentially expressed uniquely in OV-90. The investigation of these ESTs could facilitate the identification of novel chromosome 3 genes implicated in ovarian tumorigenesis.

Entities:  

Mesh:

Year:  2002        PMID: 11779836      PMCID: PMC155251          DOI: 10.1101/gr.174202

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  38 in total

1.  Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung.

Authors:  M Sugita; N Tanaka; S Davidson; S Sekiya; M Varella-Garcia; J West; H A Drabkin; R M Gemmill
Journal:  Cancer Genet Cytogenet       Date:  2000-02

2.  Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms.

Authors:  F Mertens; B Johansson; M Höglund; F Mitelman
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

3.  Expression and clinical significance of apolipoprotein D in epithelial ovarian carcinomas.

Authors:  J Vázquez; L González; A Merino; F Vizoso
Journal:  Gynecol Oncol       Date:  2000-03       Impact factor: 5.482

4.  Mutations in the arginine-rich protein gene (ARP) in pancreatic cancer.

Authors:  V Shridhar; S Rivard; X Wang; R Shridhar; C Paisley; C Mullins; L Beirnat; M Dugan; F Sarkar; O J Miller; V K Vaitkevicius; D I Smith
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

5.  Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.

Authors:  W Zheng; M P Luo; C Welt; G Lambert-Messerlian; C J Sung; Z Zhang; S Y Ying; A L Schneyer; S C Lauchlan; J C Felix
Journal:  Gynecol Oncol       Date:  1998-04       Impact factor: 5.482

6.  Normal polymorphism in the incomplete trinucleotide repeat of the arginine-rich protein gene.

Authors:  E Evron; P Cairns; N Halachmi; S A Ahrendt; A L Reed; D Sidransky
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

7.  Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas.

Authors:  G Sonoda; J Palazzo; S du Manoir; A K Godwin; M Feder; M Yakushiji; J R Testa
Journal:  Genes Chromosomes Cancer       Date:  1997-12       Impact factor: 5.006

8.  Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Authors:  M Cornarotti; G Capranico; S Bohm; S Oriana; G B Spatti; L Mariani; G Ballabio; F Zunino
Journal:  Int J Cancer       Date:  1996-08-07       Impact factor: 7.396

9.  Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.

Authors:  B R Davies; S D Worsley; B A Ponder
Journal:  Histopathology       Date:  1998-01       Impact factor: 5.087

10.  H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.

Authors:  X C Wang; R Katso; R Butler; A M Hanby; R Poulsom; T Jones; D Sheer; T S Ganesan
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

View more
  3 in total

1.  Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.

Authors:  Paule Héléna Yoffou; Lydia Edjekouane; Liliane Meunier; André Tremblay; Diane Michèle Provencher; Anne-Marie Mes-Masson; Euridice Carmona
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

2.  Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Authors:  Neal Al Cody; Magdalena Zietarska; Ali Filali-Mouhim; Diane M Provencher; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  BMC Med Genomics       Date:  2008-08-07       Impact factor: 3.063

3.  Comparative proteome analysis of human epithelial ovarian cancer.

Authors:  Jean-Philippe Gagné; Chantal Ethier; Pierre Gagné; Geneviève Mercier; Marie-Eve Bonicalzi; Anne-Marie Mes-Masson; Arnaud Droit; Eric Winstall; Maxim Isabelle; Guy G Poirier
Journal:  Proteome Sci       Date:  2007-09-24       Impact factor: 2.480

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.